GOU-ON, 2.5 ml syringe

GO-ONR is a sterile, non-pyrogenic sodium hyaluronate solution in a ready-to-use syringe containing 2.5 ml of 1% sodium hyaluronate solution, which is obtained from Streptococus equi culture by fermentation and subsequent purification.

Indications

It is used to improve the visco-elastic properties of synovial fluid in the treatment of osteoarthritis/osteoarthritis (gonarthrosis, coxarthrosis, osteoarthrosis of carpal and temporomandibular joints, secondary posttraumatic osteoarthrosis of large and medium joints, osteoarthrosis against orthopedic anomalies, secondary arthrosis in arthritis).

Active ingredient

Composition

Active ingredient:

1% sodium hyaluronan solution 2.5 ml (25 mg);

derived from Streptococcus Equi culture by fermentation and subsequent purification;

How to take, the dosage

The GO-ON product should be injected into the affected joint 5 times at weekly intervals.

Multiple joints can be treated at the same time.

Depending on the severity of the joint disease, the effect of the drug after a course of five injections can last up to six months or more.

Retreatment can be repeated if necessary.

If a joint effusion is formed, it is recommended to perform a puncture, immobilize the joint, place an ice bladder and/or inject corticosteroids into the joint.

The treatment with GO-ON can be repeated after 2-3 days.

As long as the integrity of the sterile container is not compromised, the contents, and the surface of the filled syringe remain sterile.

Interaction

There is a known incompatibility between sodium hyaluronate and quaternary ammonium salts, such as benzalkonium chloride, which can be used for skin disinfection.

This is why GO-ONR should never come in contact with these substances and should not be used to clean medical or surgical instruments, as hyaluronic acid can precipitate in their presence.

Special Instructions

Some of the preparations of Sodium Hyaluronate contain small amounts of chicken protein, so caution should be exercised when treating patients with appropriate hypersensitivity. Particular attention should be given to patients with hypersensitivity to the medication.

Sodium Hyaluronate should not be administered if there is significant intra-articular effusion.

General precautions for intra-articular injections should be observed. Disinfectants containing quaternary ammonium salts should not be used when treating the skin prior to injection.

The solution should be warmed to room temperature before injection.

Sodium Hyaluronate should be gently injected into the joint cavity. It should not be injected extraarticularly, including into synovial tissues or joint capsule. In this case there may be local adverse reactions. The drug must be prevented from entering the blood vessels!

As after any other invasive joint procedure, after sodium Hyaluronate injection the patient is advised to be gentle and avoid excessive stress on the joint for a few days.

Do not use if the pre-filled syringe or sterile packaging is damaged.

The efficacy of a course of treatment containing fewer than three injections has not been established.

The efficacy and safety of Sodium Hyaluronate when used for indications other than osteoarthritis or osteoarthritis has not been established.

Sodium Hyaluronate has not been used to treat pregnant women or children under 18 years of age.

Anesthetics or other pharmacological agents should not be injected into the affected joint cavity during treatment with Sodium Hyaluronate.

Contraindications

Hypersensitivity to one of the ingredients of the drug, inflammatory joint diseases (e.g., rheumatoid arthritis or Bechterew disease).

Side effects

Sodium Hyaluronate has excellent tolerability.

The complete absence of toxic and mutagenic reactions has been shown in clinical studies. Thanks to the syringe-pen form of release the possibility of secondary infection during injection is minimized.

Possible adverse reactions (usually goes away within a few days):

Pregnancy use

While no teratogenic effects of this drug have been identified in animals, the safety of its use in women has not been determined.

The drug is recommended with caution for pregnant women or women planning to become pregnant. It has been found that sodium hyaluronan in animals is excreted with milk, so it is not recommended to breastfeed during the treatment period.

Similarities